Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000412005

Medchemexpress LLC Perhexiline (maleate) | 6724-53-4 | 100.0% | 1 ML
SDP

Catalog No. 5000412005
Encompass_Preferred

Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. It induces mitochondrial dysfunction and apoptosis in hepatic cells. It can cross the blood-brain barrier (BBB) and exhibits anti-tumor activity. Perhexiline maleate is used in the research of cancers and cardiovascular diseases like angina.

  • Orally active CPT1 and CPT2 inhibitor
  • Reduces fatty acid metabolism
  • Induces mitochondrial dysfunction and apoptosis in hepatic cells
  • Can cross the blood-brain barrier (BBB)
  • Shows anti-tumor activity
  • Useful in research for cancers and cardiovascular diseases like angina

Catalog No. 50-004-12005 Supplier Medchemexpress LLC Supplier No. HYB1334A10MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. It induces mitochondrial dysfunction and apoptosis in hepatic cells. It can cross the blood-brain barrier (BBB) and exhibits anti-tumor activity. Perhexiline maleate is used in the research of cancers and cardiovascular diseases like angina.

  • Orally active CPT1 and CPT2 inhibitor
  • Reduces fatty acid metabolism
  • Induces mitochondrial dysfunction and apoptosis in hepatic cells
  • Can cross the blood-brain barrier (BBB)
  • Shows anti-tumor activity
  • Useful in research for cancers and cardiovascular diseases like angina

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.